Literature DB >> 25100719

Characterization of the influence of mediator complex in HIV-1 transcription.

Alba Ruiz1, Eduardo Pauls1, Roger Badia1, Eva Riveira-Muñoz1, Bonaventura Clotet1, Ester Ballana1, José A Esté2.   

Abstract

HIV-1 exploits multiple host proteins during infection. siRNA-based screenings have identified new proteins implicated in different pathways of the viral cycle that participate in a broad range of cellular functions. The human Mediator complex (MED) is composed of 28 elements and represents a fundamental component of the transcription machinery, interacting with the RNA polymerase II enzyme and regulating its ability to express genes. Here, we provide an evaluation of the MED activity on HIV replication. Knockdown of 9 out of 28 human MED proteins significantly impaired viral replication without affecting cell viability, including MED6, MED7, MED11, MED14, MED21, MED26, MED27, MED28, and MED30. Impairment of viral replication by MED subunits was at a post-integration step. Inhibition of early HIV transcripts was observed by siRNA-mediated knockdown of MED6, MED7, MED11, MED14, and MED28, specifically affecting the transcription of the nascent viral mRNA transactivation-responsive element. In addition, MED14 and MED30 were shown to have special relevance during the formation of unspliced viral transcripts (p < 0.0005). Knockdown of the selected MED factors compromised HIV transcription induced by Tat, with the strongest inhibitory effect shown by siMED6 and siMED14 cells. Co-immunoprecipitation experiments suggested physical interaction between MED14 and HIV-1 Tat protein. A better understanding of the mechanisms and factors controlling HIV-1 transcription is key to addressing the development of new strategies required to inhibit HIV replication or reactivate HIV-1 from the latent reservoirs.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Host Factor; Human Immunodeficiency Virus (HIV); RNA Polymerase II; RNA Silencing; RNAP II; Tat; Transcription; Viral Transcription

Mesh:

Substances:

Year:  2014        PMID: 25100719      PMCID: PMC4183804          DOI: 10.1074/jbc.M114.570341

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

2.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.

Authors:  Y Zhu; T Pe'ery; J Peng; Y Ramanathan; N Marshall; T Marshall; B Amendt; M B Mathews; D H Price
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

3.  The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme.

Authors:  T P Cujec; H Cho; E Maldonado; J Meyer; D Reinberg; B M Peterlin
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

4.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

Review 5.  Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.

Authors:  A Marcello; M Zoppé; M Giacca
Journal:  IUBMB Life       Date:  2001-03       Impact factor: 3.885

6.  Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro.

Authors:  M Witvrouw; J C Schmit; B Van Remoortel; D Daelemans; J A Esté; A M Vandamme; J Desmyter; E De Clercq
Journal:  AIDS Res Hum Retroviruses       Date:  1997-01-20       Impact factor: 2.205

7.  P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.

Authors:  H S Mancebo; G Lee; J Flygare; J Tomassini; P Luu; Y Zhu; J Peng; C Blau; D Hazuda; D Price; O Flores
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

8.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts.

Authors:  M Adams; L Sharmeen; J Kimpton; J M Romeo; J V Garcia; B M Peterlin; M Groudine; M Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells.

Authors:  J A Esté; M Witvrouw; J Tu; J Desmyter; E De Clercq; A M Vandamme
Journal:  AIDS Res Hum Retroviruses       Date:  1995-11       Impact factor: 2.205

Review 10.  The Mediator complex and transcription regulation.

Authors:  Zachary C Poss; Christopher C Ebmeier; Dylan J Taatjes
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-10-03       Impact factor: 8.250

View more
  18 in total

1.  Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.

Authors:  Nadejda Beliakova-Bethell; Amey Mukim; Cory H White; Savitha Deshmukh; Hosiana Abewe; Douglas D Richman; Celsa A Spina
Journal:  J Biol Chem       Date:  2019-02-11       Impact factor: 5.157

2.  Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages.

Authors:  Alba Ruiz; Eduardo Pauls; Roger Badia; Javier Torres-Torronteras; Eva Riveira-Muñoz; Bonaventura Clotet; Ramon Martí; Ester Ballana; José A Esté
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  HIV Transcription Is Independent of Mediator Kinases.

Authors:  Daniele C Cary; Mona Rheinberger; Ajda Rojc; B Matija Peterlin
Journal:  AIDS Res Hum Retroviruses       Date:  2019-05-29       Impact factor: 2.205

Review 4.  Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.

Authors:  Guillaume Mousseau; Susana T Valente
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

5.  Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource.

Authors:  Megan Druce; Chantal Hulo; Patrick Masson; Paula Sommer; Ioannis Xenarios; Philippe Le Mercier; Tulio De Oliveira
Journal:  Database (Oxford)       Date:  2016-04-17       Impact factor: 3.451

6.  The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.

Authors:  Shraddha Sharma; Santosh K Patnaik; Robert T Taggart; Bora E Baysal
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

7.  RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages.

Authors:  Maria Pujantell; Eva Riveira-Muñoz; Roger Badia; Marc Castellví; Edurne Garcia-Vidal; Guillem Sirera; Teresa Puig; Cristina Ramirez; Bonaventura Clotet; José A Esté; Ester Ballana
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

8.  A single-molecule view of transcription reveals convoys of RNA polymerases and multi-scale bursting.

Authors:  Katjana Tantale; Florian Mueller; Alja Kozulic-Pirher; Annick Lesne; Jean-Marc Victor; Marie-Cécile Robert; Serena Capozi; Racha Chouaib; Volker Bäcker; Julio Mateos-Langerak; Xavier Darzacq; Christophe Zimmer; Eugenia Basyuk; Edouard Bertrand
Journal:  Nat Commun       Date:  2016-07-27       Impact factor: 14.919

9.  Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS).

Authors:  Aditi Shendre; Howard W Wiener; Marguerite R Irvin; Bradley E Aouizerat; Edgar T Overton; Jason Lazar; Chenglong Liu; Howard N Hodis; Nita A Limdi; Kathleen M Weber; Stephen J Gange; Degui Zhi; Michelle A Floris-Moore; Ighovwerha Ofotokun; Qibin Qi; David B Hanna; Robert C Kaplan; Sadeep Shrestha
Journal:  PLoS One       Date:  2017-12-04       Impact factor: 3.240

10.  Genome-Wide Association Study in Vestibular Neuritis: Involvement of the Host Factor for HSV-1 Replication.

Authors:  Dan Rujescu; Annette M Hartmann; Ina Giegling; Bettina Konte; Marko Herrling; Susanne Himmelein; Michael Strupp
Journal:  Front Neurol       Date:  2018-07-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.